Filing Details
- Accession Number:
- 0001140361-16-053995
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-02-18 18:35:16
- Reporting Period:
- 2016-02-16
- Filing Date:
- 2016-02-18
- Accepted Time:
- 2016-02-18 18:35:16
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1437402 | Ardelyx Inc. | ARDX | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1611184 | Mark Kaufmann | C/O Ardelyx, Inc. 34175 Ardenwood Blvd, Suite 100 Fremont CA 94555 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2016-02-16 | 5,000 | $0.54 | 6,282 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2016-02-16 | 5,000 | $10.25 | 1,282 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2016-02-16 | 5,000 | $0.00 | 5,000 | $0.54 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 115,894 | 2021-08-11 | No | 4 | M | Direct |
Footnotes
- Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 17, 2015.
- This transaction was executed in multiple trades in prices ranging from $10.14 to $10.37, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- The option is fully vested and exercisable.
Billionaire Hedge Funds
